Theon Pharmaceuticals Limited

Theon Pharmaceuticals Limited, established on May 26, 2005, is a public unlisted company headquartered in Chandigarh, India. The company is classified under the Corporate Identification Number (CIN) U24231CH2005PLC028465. Its authorized share capital is ₹50 million, with a paid-up capital of ₹43.75 million. Theon Pharmaceuticals specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is committed to quality, adhering to WHO-GMP and ISO 9001:2008 standards, ensuring that its products meet international quality benchmarks.

Theon Pharmaceuticals operates a state-of-the-art manufacturing facility located in the excise-free zone of Himachal Pradesh, India. This facility spans 4.5 acres and is equipped with modern infrastructure for the production of tablets, capsules, injectables, and dry syrup formulations. The plant has an impressive annual production capacity, including 2,000 million tablets, 1,000 million capsules, 100 million injectables, and 50 million dry syrup units. The company's product portfolio is diverse, encompassing therapeutic segments such as antibiotics, anti-inflammatory agents, and anti-diabetics. Theon Pharmaceuticals exports its products to over 60 countries, including regions in Africa, Southeast Asia, Latin America, and the CIS countries, reflecting its significant global presence.

Theon Pharmaceuticals Limited's manufacturing facility is strategically located in the excise-free zone of Himachal Pradesh, India. This location offers tax advantages and operational efficiencies, contributing to the company's competitive edge in the pharmaceutical manufacturing sector. The plant is segmented into dedicated blocks for General formulations, Penicillins (Beta Lactams), and Cephalosporins, ensuring specialized production environments that adhere to stringent quality standards. Theon Pharmaceuticals has recently expanded its capabilities with the addition of a Dry Powder Injectable manufacturing facility, fully compliant with all regulatory and statutory requirements. This expansion underscores the company's commitment to meeting diverse market needs and adhering to global quality standards.

Theon Pharmaceuticals Limited is led by a team of experienced professionals committed to the company's mission of delivering high-quality pharmaceutical products. The leadership team includes:

• Mr. Amit Bansal: CEO
• Mr. Punit Bansal: Director
• Mr. Anshul Bansal: Director
• Mr. Manish Bansal: Director

These leaders bring a wealth of experience and strategic vision to the company, driving its growth and ensuring adherence to quality standards.

Theon Pharmaceuticals Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and certifications to access these markets, demonstrating its commitment to meeting international standards. In the United States, Theon Pharmaceuticals has registered its manufacturing facilities with the FDA, ensuring compliance with Good Manufacturing Practices (GMP). The company has also filed Abbreviated New Drug Applications (ANDAs) for its generic formulations, facilitating market entry. In the European Union, Theon Pharmaceuticals has obtained EU GMP certificates, allowing it to market its products across EU member states. The company is also in the process of obtaining approvals from other regulatory bodies, such as the UK's MHRA, Australia's TGA, and Japan's PMDA, to further expand its market reach. These efforts reflect Theon Pharmaceuticals' strategic focus on penetrating regulated markets and adhering to their stringent regulatory requirements.

Theon Pharmaceuticals Limited has strategically expanded its footprint into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has been instrumental in facilitating access to these markets, as it ensures that products meet international quality benchmarks. By obtaining WHO prequalification, Theon Pharmaceuticals has enhanced its credibility and trustworthiness among healthcare providers and regulatory authorities in these regions. This strategic approach has enabled the company to establish a strong presence in emerging markets, contributing to its overall growth and global reach.

Theon Pharmaceuticals Limited has adopted a strategic approach to geographic diversification, aiming to mitigate risks associated with over-reliance on any single market. By exporting to over 60 countries, including regions in Africa, Southeast Asia, Latin America, and the CIS countries, the company has effectively spread its market presence. This diversification strategy not only reduces concentration risk but also positions Theon Pharmaceuticals to capitalize on growth opportunities in various global markets. The company's focus on obtaining regulatory approvals and certifications in multiple regions underscores its commitment to global expansion and adherence to international quality standards.

Theon Pharmaceuticals Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with the agency's Good Manufacturing Practices (GMP). The company has also filed Abbreviated New Drug Applications (ANDAs) for its generic formulations, facilitating market entry into the U.S. market. These regulatory filings demonstrate Theon Pharmaceuticals' commitment to meeting the stringent requirements set forth by the FDA, reflecting its dedication to quality and regulatory compliance. The company's proactive approach in obtaining FDA approvals positions it favorably in the competitive U.S. pharmaceutical market.

Theon Pharmaceuticals Limited has obtained WHO-GMP certification, affirming its adherence to international quality standards in pharmaceutical manufacturing. This certification is crucial for accessing global markets and underscores the company's commitment to quality. In addition to WHO-GMP, Theon Pharmaceuticals has secured EU GMP certificates, enabling it to market its products across European Union member states. These certifications reflect the company's dedication to maintaining high manufacturing standards and its strategic focus on expanding its presence in regulated markets.

Theon Pharmaceuticals Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. These licenses authorize the company to produce pharmaceutical formulations for both domestic and export markets. The company's adherence to CDSCO regulations ensures that its products meet national quality standards. Additionally, Theon Pharmaceuticals has obtained export No Objection Certificates (NOCs), facilitating the export of its products to various international markets. These regulatory approvals demonstrate the company's compliance with Indian pharmaceutical regulations and its commitment to quality and safety.

As of March 28, 2026, there are no publicly available records indicating that Theon Pharmaceuticals Limited has received any Form 483 observations, warning letters, or import alerts from regulatory authorities such as the FDA. This absence of adverse regulatory actions suggests that the company maintains a strong compliance record and adheres to the regulatory standards set by health authorities. The company's proactive approach to quality assurance and regulatory compliance contributes to its positive standing in the pharmaceutical industry.

Theon Pharmaceuticals Limited operates in a competitive landscape, with several key players in the pharmaceutical manufacturing sector. While specific market share data is not publicly available, Theon Pharmaceuticals distinguishes itself through its WHO-GMP and ISO 9001:2008 certifications, extensive product portfolio, and strategic focus on both domestic and international markets. The company's commitment to quality and regulatory compliance positions it favorably against competitors, enabling it to capture a significant share of the global pharmaceutical market.

Theon Pharmaceuticals Limited's key differentiators include its adherence to WHO-GMP and ISO 9001:2008 standards, ensuring high-quality manufacturing processes. The company's diverse product portfolio, encompassing various therapeutic segments, allows it to meet a wide range of market needs. Additionally, Theon Pharmaceuticals' strategic focus on obtaining regulatory approvals in multiple regions, including the U.S., EU, and emerging markets, enhances its global reach and credibility. These factors collectively contribute to the company's competitive advantage in the pharmaceutical industry.

Theon Pharmaceuticals Limited's current strategic direction focuses on expanding its presence in both regulated and emerging markets. The company's commitment to obtaining regulatory approvals, such as WHO-GMP and EU GMP certifications, reflects its dedication to meeting international quality standards. Looking ahead, Theon Pharmaceuticals aims to further diversify its product portfolio and strengthen its position in the global pharmaceutical market. The company's proactive approach to quality assurance, regulatory compliance, and market expansion positions it well for sustained growth and success in the industry.

Theon Pharmaceuticals Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a significant export volume and consistency in product quality. The company's adherence to WHO-GMP and ISO 9001:2008 standards underscores its commitment to maintaining high